FOR IMMEDIATE RELEASE

• New fellowship integrates regenerative medicine, emerging biotechnology, longevity medicine, and artificial intelligence
• Program targets physicians and point-of-care regenerative medicine providers
• Curriculum reflects ISSCA’s continued investment in advanced physician credentialing

MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a comprehensive new fellowship designed for physicians and point-of-care regenerative medicine providers.

The curriculum integrates regenerative medicine modalities, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence — reflecting what ISSCA describes as the increasingly multidisciplinary nature of modern regenerative medicine practice.

ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries. The new fellowship is positioned as the organization’s most comprehensive credential to date, intended to prepare physicians for the convergence of clinical practice, biotechnology, and computational tools.

“The physicians who will lead this field aren’t going to specialize in just one modality — they’ll need to be fluent across regenerative medicine, biotechnology, and increasingly, AI-driven clinical tools,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This fellowship is ISSCA’s answer to that shift.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About ISSCA

The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• Sponsorship connects Cellgenic to one of Latin America’s largest combined aesthetic, regenerative, and orthomolecular medicine congresses
• Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza, Buenos Aires, organized by Portal Medestética
• Event combines four concurrent programs, a commercial exhibition, and live procedural demonstrations

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Congreso Internacional Medéstetica 2026 in Buenos Aires, Argentina.

Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza in Buenos Aires and combines four concurrent programs — the XI International Medical Aesthetics Congress, IV Live Demo Day, the XI Orthomolecular and Integrative Medicine Meeting, and the XIV Cosmiatry and Applied Aesthetics Meeting — alongside a commercial exhibition and live procedural demonstrations, organized by Portal Medestética.

The sponsorship gives Cellgenic direct access to a physician audience spanning aesthetic, regenerative, and orthomolecular medicine, complementing the Company’s existing Argentina commercial operations and reinforcing its regional physician-education and product-visibility strategy.

“Medéstetica brings together exactly the physician disciplines Cellgenic serves — aesthetic, regenerative, and orthomolecular medicine — under one roof,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This sponsorship is a natural extension of the commercial footprint we’ve been building in Argentina all year.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• Sponsorship connects Cellgenic’s Argentina commercial operations to Latin America’s leading facial-rejuvenation and aesthetic-medicine congress
• Master Hub LatAm 2026 runs October 15–16 at the Hilton Buenos Aires, led by scientific director Dr. Fernando Felice
• Event draws 12+ international speakers across regenerative therapies, injectables, and longevity tracks

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Master Hub LatAm 2026, described by organizers as the most important aesthetic medicine and facial rejuvenation congress in Latin America.

Master Hub LatAm 2026 takes place October 15–16 at the Hilton Hotel in Buenos Aires, Argentina, under scientific director and founder Dr. Fernando Felice, a plastic surgeon and professor at Universidad de Buenos Aires. The 2026 program features more than 12 international speakers across sessions on regenerative therapies, advanced technologies, neuromodulators, and longevity medicine.

The sponsorship builds on Cellgenic’s July 2026 launch of regulated commercial operations in Argentina, extending the Company’s regional presence into one of the country’s highest-visibility medical-aesthetics events and giving Cellgenic direct access to the congress’s international physician and injector audience.

“Master Hub LatAm is where the region’s leading aesthetic physicians go to see what’s next,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Sponsoring this year’s congress puts Cellgenic’s regenerative technologies directly in front of that audience, right as we’re scaling our commercial operations across Argentina.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• Expansion adds local infrastructure and physician-provider relationships in Colombia
• Colombia completes a three-market Latin American expansion alongside Peru and Brazil
• Growth reflects Cellgenic’s continued investment in regional physician networks

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an operational expansion into Colombia, adding local commercial infrastructure and building physician and medical-provider relationships across the market.

The Colombia expansion follows Cellgenic’s recent moves into Peru and Brazil, and management said it completes a near-term Latin American growth phase focused on Andean and South American markets with established regenerative-medicine physician communities — several of which ISSCA has also served through its Bogotá conference programming.

Cellgenic is pursuing exclusive representation and partnership arrangements in Colombia, consistent with its approach in other markets.

“Colombia rounds out a Latin American expansion phase that’s been deliberate and market-by-market,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Between Peru, Brazil, and Colombia, Cellgenic now has meaningfully more regional reach than it did a year ago.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• New permanent operations and offices support Cellgenic’s commercial buildout in Brazil
• Brazil expansion reflects the strategic importance of one of Latin America’s largest regenerative medicine and longevity markets
• Launch builds local physician relationships and commercial infrastructure

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the establishment of permanent operations and offices in Brazil.

Brazil represents one of Latin America’s largest healthcare and aesthetic-medicine markets, and Cellgenic said the buildout includes local representation, physician relationships, and commercial infrastructure intended to support both product distribution and longer-term market development.

The Company noted that Brazil’s scale and existing regenerative-medicine physician community — reinforced by ISSCA’s own conference activity in São Paulo — make it a strategically important market within Cellgenic’s Latin American expansion plan.

“Brazil is one of the largest and most sophisticated regenerative medicine markets in Latin America,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “A permanent operational presence lets Cellgenic build the kind of long-term physician relationships that market deserves.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• Expansion establishes permanent local operations and physician representation in Peru
• Peru becomes the latest addition to Cellgenic’s Latin American commercial footprint
• Launch builds on Cellgenic’s existing regional infrastructure and physician relationships

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its expansion into Peru through the establishment of local operations and exclusive representation arrangements.

The Peru launch extends Cellgenic’s Latin American commercial network, which the Company has been building through market entries and local partnerships across the region. Cellgenic intends to develop physician and medical-provider relationships in Peru consistent with its approach in other Latin American markets.

Management said Peru fits within Cellgenic’s broader Latin American expansion strategy and represents an additional near-term commercial growth opportunity for the division.

“Peru has a strong and growing physician community interested in regenerative medicine,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Establishing a permanent presence there is a natural next step in building out Cellgenic’s Latin American network.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• Expansion adds two ISO 7-classified clean rooms to existing laboratory infrastructure
• Investment is intended to support increased manufacturing, quality systems, and product-development capacity
• Infrastructure expansion supports Cellgenic’s growing international product portfolio

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expansion of its flagship laboratory facilities in Cancun, Mexico, adding two ISO 7-classified clean rooms to the Company’s existing laboratory infrastructure.

The additional capacity is intended to support increased manufacturing capabilities, product development throughput, and quality-systems capacity as Cellgenic’s international product portfolio continues to grow — including the Company’s recently announced NK cell and MUSE cell product lines and expanded peptide delivery portfolio.

The Company characterized the investment as an important component of its long-term international growth strategy, supporting both current production volume and future product-line development.

“Manufacturing and quality infrastructure is what lets a product roadmap turn into reliable, scalable supply,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This clean room expansion in Cancun gives Cellgenic the capacity it needs to support the product lines we’ve been bringing to market this year.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

FOR IMMEDIATE RELEASE

• New portfolio adds combination peptide pens and intranasal delivery formats to Cellgenic’s peptide product line
• Delivery-format innovation, not a new peptide compound, is the core of the announcement
• Launch responds to international physician demand for more convenient peptide administration options

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a next-generation peptide delivery portfolio featuring combination peptide pens and intranasal delivery formats, developed in response to international physician and market demand for more convenient and diversified peptide administration options.

The new delivery formats expand how physicians in Cellgenic’s markets can offer peptide-based products within their practices, including applications in physician-directed optimization, longevity, and wellness contexts where legally appropriate.

Cellgenic said the innovation is centered on delivery-platform convenience and format diversification rather than new active compounds, and that the portfolio is intended to complement its existing peptide product line.

“Physicians have told us convenience and administration flexibility matter as much as the underlying formulation,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This portfolio gives Cellgenic’s physician network combination pen and intranasal options that fit more easily into their practices.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Xeno-Free Biologics Facility in Cancún, Now Producing and Distributing Six Product Lines to International Markets

COFEPRIS-Guided Laboratory Actively Shipping Exosomes, MSCs, NK Cells, and Allogeneic Fibroblasts as Company Advances Authorized Distributor Program and 2026 Pipeline Expansion Including Peptide Formulations, Secretome, and Private-Label Manufacturing

LAS VEGAS, NV / July 14th, 2026 / Regenerative Medical Technologies Group, Inc. (the “Company”) (OTCID:RMTG), a global leader in regenerative medicine solutions, today announced through its Global Stem Cells Group (GSCG) subsidiary that the Cellgenic advanced biologics manufacturing facility in Cancún, Mexico, has officially commenced full operations.

The Laboratory – believed to be the first facility in Cancún developed specifically for the external manufacturing and international distribution of biologics – is now actively producing and shipping six biologic product lines to authorized medical professionals and institutions across compliant international markets. The operational launch follows the facility’s soft opening during the ISSCA Global Regenerative Medicine Summit in September 2025, which attracted full attendance from physicians and scientists representing more than 30 countries.

The full-scale launch adds a significant manufacturing revenue stream to RMTG’s integrated business model and builds on the Company’s recent financial momentum, including Q1 2025 sales of $1.35M representing 67% growth year-over-year with operational profits of $134,000.

“This facility reflects years of deliberate planning and represents a pivotal milestone in our expansion strategy,” said David Christensen, CEO and President of RMTG. “Our goal has never been rapid expansion without structure. We built this laboratory to support physicians and institutions seeking consistent, well-documented biologics produced under carefully designed conditions – and we are now delivering on that commitment. We believe the addition of in-house manufacturing capability significantly strengthens our competitive position and our ability to generate recurring revenue across our 30-plus-country distribution network.”

Six Active Product Lines in Production

As of January 2026, the Cancún facility is actively producing and distributing the following biologic products to authorized professionals and institutions:

• Exosome Flow Series – Liquid exosomes available in multiple concentrations
• Lyophilized Exosomes – Prepared for topical and localized applications
• Umbilical Cord-Derived Mesenchymal Stem Cells (MSCs) – Cryopreserved and culture-expanded
• Natural Killer (NK) Cells – Produced under controlled freezing and handling protocols
• Allogeneic Fibroblasts – Intended for aesthetic and research-oriented applications
• Sterile Diluents – Including bacteriostatic water and saline solutions

All products are accompanied by full batch documentation, donor screening records, and handling guidelines. The facility incorporates modular cleanroom environments, controlled cold-chain logistics, structured batch documentation, and donor traceability systems developed with reference to AATB-aligned practices and COFEPRIS-guided operational frameworks. Cellgenic emphasizes that its biologics are not intended to diagnose, treat, cure, or prevent any disease and are supplied exclusively to authorized professionals and institutions in compliance with local regulations.

Xeno-Free Manufacturing: A Differentiating Standard

All biologics produced at the Cancún facility are manufactured under xeno-free conditions, meaning no animal-derived components are used at any stage of production. Cellgenic’s manufacturing philosophy emphasizes human-origin materials, controlled inputs, and fully documented sourcing processes – an approach the Company believes supports broader international acceptance and alignment with evolving regulatory expectations across multiple regions.

Benito Novas, CEO of Global Stem Cells Group and founder of Cellgenic, added: “This is what we set out to build – purpose-built infrastructure, not repurposed spaces. Physicians around the world are asking for consistent access to well-documented biologics produced under real manufacturing conditions. This facility delivers on that demand and positions Cellgenic to scale alongside the growing international adoption of regenerative medicine.”

Integrated Model: Manufacturing, Education, and Clinical Collaboration

The facility operates in close coordination with the Cellular Hope Institute, a clinical and educational center also based in Cancún under the GSCG umbrella, as well as ISSCA (International Society for Stem Cell Application), the world’s largest organization dedicated to training physicians in regenerative medicine. Through this integrated model, visiting physicians and researchers participating in ISSCA-accredited programs can observe manufacturing workflows firsthand, engage in hands-on educational sessions, and participate in structured clinical discussions related to biologics handling and responsible application.

“We expect this facility to play a meaningful role in our integrated model of manufacturing, education, and clinical collaboration,” said Sarah Barroso, Managing Director of Cellgenic. “By aligning our laboratory operations with the Cellular Hope Institute and ISSCA’s educational platform, we are contributing to greater transparency, consistency, and professional dialogue within the regenerative medicine field.”

2026 Pipeline and Growth Initiatives

Building on the momentum of the operational launch, Cellgenic has outlined an expanded product and services pipeline for 2026, including:

• Exosome-peptide combination formulations
• Multi-peptide blended delivery formats
• Cell-free conditioned media (secretome)
• Cryopreserved cell banking services
• Private-label and white-label manufacturing programs

Authorized Distributor Program

The Company has also introduced an Authorized Distributor Program designed for qualified partners operating in compliant markets. The program is structured to support long-term collaboration through educational resources, standardized documentation, and regional alignment initiatives. RMTG expects the distributor program to serve as a key driver of international growth as the Company scales its manufacturing capacity and geographic reach throughout 2026.

About Regenerative Medical Technologies Group, Inc. (RMTG)

Since the acquisition of Global Stem Cells Group (GSCG), Regenerative Medical Technology Group (RMTG) is focused on Stem Cell and Regenerative Medicine fields, covering clinical research, patient applications, along with physician training through its state-of-the-art global network of companies. The Company’s mission is to enable physicians to make the benefits of stem cell medicine a reality for patients around the world. RMTG has been educating doctors on the science and application of cell-based therapeutics for over 10 years through its professional trademarked association ISSCA (International Society for Stem Cell Application), a global network of medical professionals that leverages multinational relationships to build best practices and further the Company’s mission.

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations, product distribution, manufacturing capabilities, and medical education to capitalize on the rapidly expanding global regenerative medicine market. The Company’s Cellgenic brand offers a comprehensive portfolio of regenerative medicine products including exosomes, MSCs, and platelet-rich plasma kits produced under rigorous quality protocols.

To learn more, visit www.regenmedtechgroup.com and www.stemcellsgroup.com.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. Forward-looking statements include, but are not limited to, statements regarding planned product pipeline expansions, anticipated distributor program growth, expectations for international market penetration, projected manufacturing capacity scaling, and the Company’s broader strategic positioning in the regenerative medicine sector. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and similar expressions are intended to identify forward-looking statements.

As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, manufacturing facility performance, product pipeline development, distributor program enrollment, or international market expansion. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including but not limited to: changes in international regulatory frameworks governing biologics manufacturing and distribution; the Company’s ability to attract and retain authorized distribution partners; the successful development and commercialization of pipeline products; competitive dynamics within the regenerative medicine industry; supply chain disruptions affecting raw materials or cold-chain logistics; the Company’s ability to maintain compliance with applicable local, national, and international regulations; and general economic and market conditions.

The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contact: David Christensen, CEO and President Regenerative Medical Technologies Group, Inc. investor.relations@regenmedtechgroup.com | (800) 956-3935

Cellgenic launches regulated commercial operations in Argentina, creating a platform for biologics distribution, physician education, and regional expansion.

BOCA RATON, FL — April 26, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”), through its wholly owned subsidiary Global Stem Cells Group and its commercial division Cellgenic, today announced a major expansion of its Latin American operations with the establishment of Cellgenic’s commercial platform in Argentina.

The expansion follows the completion of regulatory and operational milestones that allow Cellgenic to commercialize qualifying biologic and regenerative medicine products through licensed medical practitioners in compliance with applicable Argentine regulations.

The Company believes this represents one of the most significant strategic initiatives in Cellgenic’s international growth strategy and positions Argentina to become one of its principal operating hubs for South America.

“Argentina represents a unique opportunity for Cellgenic,” said David Christensen, Chief Executive Officer of Regenerative Medical Technology Group. “The combination of scientific talent, established clinical infrastructure, and a supportive regulatory framework creates an environment where we believe we can significantly expand physician access to advanced regenerative medicine products while building a scalable commercial operation throughout the region.”

Unlike many markets where regulatory uncertainty has limited physician adoption of regenerative medicine products, Cellgenic’s operational platform is designed to provide physicians with compliant access to high-quality biologic products supported by education, technical resources, and commercial infrastructure.

As part of the expansion, Cellgenic expects to:

• Expand its commercial sales organization throughout Argentina;
• Conduct physician education conferences, workshops and certification programs in collaboration with ISSCA;
• Develop new clinical collaborations and scientific case studies;
• Increase physician adoption of regenerative medicine products;
• Expand distribution capabilities throughout Argentina and neighboring Latin American markets; and
• Establish Argentina as one of Cellgenic’s primary regional centers for future growth.

The Company believes that regulatory compliance, physician education, and commercial infrastructure are critical components required for widespread adoption of regenerative medicine technologies. By integrating these elements into a unified operating platform, Cellgenic seeks to accelerate market development while supporting physicians practicing within applicable regulatory guidelines.

This initiative also strengthens the strategic relationship between Cellgenic’s commercial organization and ISSCA’s physician education platform. Through conferences, advanced certification programs, and hands-on training events, the Company expects to significantly increase physician engagement while supporting continued adoption of regenerative medicine technologies.

The Argentina expansion aligns with RMTG’s broader strategy of building an integrated global regenerative medicine ecosystem that combines physician education, biologics commercialization, laboratory capabilities, and international distribution. The Company currently operates across more than 30 countries and continues expanding its commercial footprint through strategic regional hubs.

“We are not simply entering another country,” added Christensen. “We are establishing the infrastructure necessary to support long-term physician education, commercialization, scientific collaboration, and continued expansion throughout Latin America. We believe Argentina will become an important cornerstone of Cellgenic’s international growth strategy for years to come.”

About Cellgenic

Cellgenic, a division of Global Stem Cells Group and Regenerative Medical Technology Group (OTC: RMTG), develops and commercializes regenerative medicine technologies, biologics, cell therapy products, exosomes, peptides, and related medical solutions for physicians and clinics worldwide.

About Regenerative Medical Technology Group

Regenerative Medical Technology Group, Inc. (OTC: RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated commercial expansion, future physician adoption, expected market opportunities, operational growth, revenue potential, geographic expansion, and other statements that are not historical facts. Actual results may differ materially due to various risks and uncertainties, including regulatory developments, market acceptance, operational execution, competitive conditions, economic factors, and other risks detailed in the Company’s filings with OTC Markets and applicable regulatory authorities.